Semaglutide is a recent GLP-1 analog with a prolonged half-life of approximately 1 week, that is widely used for the treatment of type 2 diabetes and obesity (Anam et al. 2022; Rubino et al. 2021). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.